Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with HR-positive/HER2-negative EBC. An ongoing positive trend for improved OS in favor of ribociclib + NSAI was observed.
Authors
- Michael Untch (ORCID: https://orcid.org/0000-0002-1233-1267)
- Juan Pablo Zarate (ORCID: https://orcid.org/0009-0002-2130-7290)
- Sherene Loi (ORCID: https://orcid.org/0000-0001-6137-9171)
- Gonzalo Spera
- Dennis J. Slamon (ORCID: https://orcid.org/0000-0002-6330-498X)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Gabriel N. Hortobágyi (ORCID: https://orcid.org/0000-0002-4873-4412)
- Denise A. Yardley (ORCID: https://orcid.org/0000-0002-8664-3458)
- Chiun‐Sheng Huang (ORCID: https://orcid.org/0000-0002-6557-211X)
- John Paul Crown (ORCID: https://orcid.org/0000-0002-3125-7613)
- S. Chia
- Sara A. Hurvitz (ORCID: https://orcid.org/0000-0001-7808-7191)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Doug N. Halligan (ORCID: https://orcid.org/0000-0003-0677-4042)
- Zheng Li (ORCID: https://orcid.org/0000-0002-8837-0318)
- Miguel Martín (ORCID: https://orcid.org/0000-0001-9237-3231)
- Carlos H. Barrios (ORCID: https://orcid.org/0000-0001-6021-667X)
- Amit Bardia (ORCID: https://orcid.org/0000-0002-0841-9442)
- R Moroose
- Daniil Stroyakovskii
- F. Visco
Institutions
- National Coalition for Cancer Survivorship (US)
- The University of Texas MD Anderson Cancer Center (US)
- Orlando Health (US)
- University of California, Los Angeles (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Washington (US)
- UCLA Health (US)
- Peter MacCallum Cancer Centre (AU)
- Seoul National University Hospital (KR)
- Fred Hutch Cancer Center (US)
- Sarah Cannon (US)
- St. Vincent's University Hospital (IE)
- Novartis (United States) (US)
- National Taiwan University Hospital (TW)
- Comprehensive Cancer Center Erlangen (DE)
- Novartis (Ireland) (IE)
- Helios Hospital Berlin-Buch (DE)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- GEICAM – Spanish Breast Cancer Group (ES)
- Moscow City Oncology Hospital №62 (RU)
- Seattle University (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105858
- Citations
- 13
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 19.74